Consolidated Financial Results for the Three Months Ended March 31, 2026 [IFRS]5/13 15:30TDnetPDF(1,015KB)
PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration Partner4/20 15:30TDnetPDF(108KB)
Notice Regarding the Management Briefing Following the 20th Ordinary General Meeting of Shareholders3/19 8:00TDnetPDF(102KB)
Consolidated Financial Results for the Fiscal Year Ended December 31, 2025 [IFRS]2/16 15:45TDnetPDF(2MB)
Notice of an Additional Contribution to the Employee Stock Ownership Plan (J-ESOP)2/16 15:45TDnetPDF(141KB)
Consolidated Financial Results for the Nine Months Ended September 30, 2025[IFRS]2025/11/12TDnetPDF(2MB)
(Correction)Regarding the Cause Analysis and Implementation of Recurrence Prevention Measures Based on the Findings of the SIC2025/10/23TDnetPDF(106KB)
Regarding the Cause Analysis and Implementation of Recurrence Prevention Measures Based on the Findings of the Special Investigation Committee2025/10/23TDnetPDF(315KB)
[Summary]Receipt of the Investigation Report from the Special Investigation Committee and Future Actions2025/8/6TDnetPDF(119KB)
Consolidated Financial Results for the Six Months Ended June 30, 2025 [IFRS]2025/8/6TDnetPDF(1,022KB)
Consolidated Financial Results for the Three Months Ended March 31, 2025 [IFRS]2025/5/13TDnetPDF(880KB)